[Federal Register: June 22, 2006 (Volume 71, Number 120)]
[Notices]
[Page 35922-35924]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr22jn06-94]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of Federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Beta-Amyloid PET Imaging Agents
Description of Technology: Available for licensing and commercial
development are two novel classes of compounds useful as radioligands
for in vivo imaging of beta-amyloid (A[beta]) peptides and plaques in
humans.
[[Page 35923]]
[GRAPHIC] [TIFF OMITTED] TN22JN06.002
Beta-amyloid peptide deposition in the brain is a pathological
feature of Alzheimer's disease (AD). Early detection of beta-amyloid
load in patients with suspected AD is vital to initiating early
treatment, which can improve cognitive function and quality of life for
many patients.
The invention describes novel derivatives of
imidazopyridinylbenzeneamine (IMPY) and benzothizolylbenzeneamine
(BTA), which demonstrate high in vitro binding affinity to human beta-
amyloid. The difference between existing IMPY compounds and the novel
derivatives is the substitution of an aryl halide with an aryl
thioether group and replacement of a sulfur group of the pyridine ring
with a nitrogen group. The new classes of compounds have the potential
of providing improved amyloid imaging agents for Positron Emission
Tomography (PET) with higher specificity for amyloid, low background
noise, better entry into the brain and improved labeling efficiency.
In addition to the novel compounds, the invention also includes:
(1) A new method of synthesizing the IMPY derivatives, using palladium
as a catalyst, (2) methods of imaging beta-amyloid deposits in the
brain by in vivo PET, magnetic reasonance imaging (MRI) and other
imaging methods involving the use of these compounds, and (3) and
methods of labeling these compounds with radiotracers ([11-C] and [18-
F]).
Inventors: Lisheng Cai (NIMH), Victor Pike (NIMH), and Robert Innis
(NIMH).
Publications:
1. Nichols L, Pike VW, Cai L, Innis RB. (2006) ``Imaging and In
Vivo Quantitation of beta-Amyloid: An Exemplary Biomarker for
Alzheimer's Disease?,'' Biol Psychiatry. [E-pub ahead of print].
2. Toyoma H, et al. (2006) ``PET imaging of brain with the beta-
amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of
Alzheimer's disease,'' Eur J Nucl Med Mol Imaging. 32(5), 593-600.
3. Cai L, et al. (2004) ``Synthesis and Evaluation of Two\18\ F-
Labeled 6-Iodo-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyidine
Derivatives as Prospective Radioligands for -Amyloid in Alzheimer's
Disease,'' J Med Chem, 47 (9), 2208-2218.
Patent Status: U.S. Provisional Application filed 21 Apr 2006 (HHS
Reference No. E-156-2006/0-US-01).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Michael Shmilovich; 301/435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The NIMH Molecular Imaging
Branch is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate, or
commercialize Beta-Amyloid PET Imaging Agents. Please contact Suzanne
Winfield at winfiels@mail.nih.gov for more information.
Carbohydrate-Encapsulated Quantum Dots for Cell-Specific Biological
Imaging
Description of Technology: Available for licensing is intellectual
property covering carbohydrate-encapsulated quantum dots (QD) for use
in medical imaging and methods of making the same. Certain
carbohydrates, especially those included on tumor glycoproteins are
known to have affinity for certain cell types. One notable glycan used
in the present invention is the Thomsen-Freidenreich disaccharide
(Galb1-3GalNAc) that is readily detectable in 90% of all primary human
carcinomas and their metastases. These glycans can be exploited for
medical imaging. Quantum Dots (QDs) are semiconductor nanocrystals
(CdSe or CdTe) with detectable luminescent properties. Encapsulating
luminescent QDs with target-specific glycans permits efficient imaging
of the tissue to which the glycans bind with high affinity. Accurate
imaging of diseased cells (e.g., primary and metastatic tumors) is of
primary importance in disease management. The inventors describe a
method for enhancing the luminescence of carbohydrate-encapsulated QDs
by addition of specific functional units in a novel synthesis of hybrid
CdTe-based core-shell semiconductor nanocrystals.
Inventors: Joseph Barchi and Sergey Svarovsky (NCI).
Patent Status: PCT Application No. PCT/US03/34897 filed 05 Nov 2003
(HHS Reference No. E-325-2003/0-PCT-01).
[[Page 35924]]
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Michael Shmilovich; 301/435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute,
Center for Cancer Research, Laboratory of Medicinal Chemistry is
seeking statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
carbohydrate-encapsulated quantum dots. Please contact Dr. Melissa
Maderia by phone: (301) 846-5465 or fax: (301) 846-6820 or e-mail:
maderiam@mail.nih.gov for more information.
Dated: June 14, 2006.
David R. Sadowski,
Acting Director, Division of Technology Development and Transfer,
Office of Technology Transfer, National Institutes of Health.
[FR Doc. 06-5579 Filed 6-21-06; 8:45 am]
BILLING CODE 4140-01-M